hengrui glp-1 Kailera, to advance oral obesity drug into 2 new trials Hengrui Pharma and Kailera Therapeutics

This built-in safety mechanism means the risk of hypoglycemia from GLP-1 monotherapy is extremely low, even with slightly early dosing

Furthermore, the improvements in glucose homeostasis following prebiotic treatment are dependent on GLP-1R signaling, implicating that prebiotic-induced alterations in the microbiome restore the gutbrain axis 257

Remove the needle from your skin

doi: 10.1042/bj3480607

Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake

In fact, most reports show a reduction in rates, but I would never argue with someone who says we need to learn more